Summary of Product Characteristics

1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Canixin L suspension for injection for dogs

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

Active substances:
Suspension:
Inactivated *Leptospira interrogans*:

- serogroup Canicola serovar Canicola, strain 601903	4350 - 7330 U*
- serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain 601895	4250 - 6910 U*

* Antigenic mass ELISA units

Excipients
For the full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Suspension for injection.
Suspension: Translucent liquid.

4 CLINICAL PARTICULARS

4.1 Target Species

Dog.

4.2 Indications for use, specifying the target species

For active immunisation of dogs from 8 weeks of age to:
- prevent mortality and reduce infection, clinical signs, kidney colonisation, renal lesions and urine shedding of *Leptospira* Canicola:
- reduce infection, clinical signs, kidney colonisation and urine shedding of *Leptospira* Icterohaemorrhagiae;

Onset of immunity:
The onset of immunity has been demonstrated from 5 weeks for *Leptospira* Canicola and 2 weeks for *Leptospira* Icterohaemorrhagiae;

Duration of immunity:
The duration of immunity lasts for one year after the primary vaccination for all components.
In the one-year duration of immunity studies there was no significant difference between vaccinated and control dogs in reduction of kidney colonisation for *Leptospira* Canicola and *Leptospira* Icterohaemorrhagiae, nor in renal lesions and urine shedding for *Leptospira* Canicola.

4.3 Contraindications

None.

4.4 Special warnings for each target species

None.

4.5 Special precautions for use

Special precautions for use in animals:
Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

A transient swelling (≤ 4 cm) or slight diffuse local oedema which resolves spontaneously within 1 to 2 weeks was commonly observed in safety studies, in rare cases associated with pain or pruritus.
Some transient post-vaccinal lethargic states were commonly observed in clinical trials.
Hyperthermia or digestive disturbances such as anorexia, diarrhoea or vomiting were reported in rare cases during clinical trials.
Hypersensitivity reactions have been reported in very rare cases from spontaneous reports. In case of such an allergic or anaphylactic reaction, appropriate symptomatic treatment should be administered.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)

- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Do not use during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interactions

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with Virbac's vaccines against canine distemper virus (CDV), canine adenovirus (CAV), canine parvovirus (CPV) and canine parainfluenza virus (CPiV), if available.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case-by-case basis.

4.9 Amounts to be administered and administration route

Shake gently and administer immediately one dose of 1 ml subcutaneously according to the following vaccination schedule:

Primary vaccination course:
- first injection from 8 weeks of age,
- second injection 3 or 4 weeks later.

When active immunisation against CDV, CAV, CPV and CPiV is also required, one dose of the product can be used to reconstitute one dose of Virbac's freeze-dried vaccines containing CDV, CAV-2, CPV and CPiV components. After reconstitution, shake gently (the reconstituted product is slightly pinkish beige) and administer immediately one dose of 1 ml subcutaneously according to the same vaccination schedule: 2 injections 3 to 4 weeks apart from 8 weeks of age.

Annual re-vaccination:
One booster injection of a single dose should be given 1 year after the second injection and annually thereafter.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Not applicable.

4.11 Withdrawal period(s)

Not applicable.

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

ATCvet code QI07AB01.
Pharmacotherapeutic group: Immunologicals for Canidae, Inactivated bacterial vaccines for dogs.

To stimulate active immunity against *Leptospira interrogans* serogroup Canicola and *Leptospira interrogans* serogroup Icterohaemorrhagiae in dogs.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Suspension:
Sodium hydroxide
Sucrose
Dipotassium phosphate
Potassium dihydrogen phosphate
Tryptone
Water for injections

6.2 Major incompatibilities

Do not mix the vaccine with any other veterinary medicinal product, except those mentioned in 4.8.

6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

6.4 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.

6.5 Nature and composition of immediate packaging

Type I glass vial containing 1 ml of suspension closed by a butyl-elastomer stopper and sealed with an aluminium cap, in a plastic or cardboard box.
Pack sizes:
1 vial of suspension
10 vials of suspension
25 vials of suspension
50 vials of suspension

100 vials of suspension
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Virbac
1ère avenue
2065 M LID
06516 Carros
France

8 MARKETING AUTHORISATION NUMBER(S)

VPA10988/102/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 24th March 2017

10 DATE OF REVISION OF THE TEXT

August 2018